Subject characteristics
| SRL172 | Placebo | |
| Subjects n | 12 | 12 |
| Age yrs | 33.7 (20–51) | 35.8 (21–53) |
| Time since diagnosis yrs | 21 (10–45) | 22.75 (2–44) |
| Asthma severity | ||
| Mild | 9 | 6 |
| Moderate | 2 | 6 |
| FEV1 mean±sd % pred | 92±10 | 92±12 |
| PC20 histamine mg·mL−1 | 1.17 | 1.81 |
| mean (geometric range) | (0.65–2.69) | (0.35–13.5) |
Data are provided as n or mean (range) unless otherwise stated
SRL172: Mycobacterium vaccae
FEV1: forced expiratory volume in one second
% pred: % predicted
PC20 provocotion dose causing a 20% fall in FEV1